The Trump administration's recent announcement of national security investigations into pharmaceutical imports has set up a potential collision course with one of the most significant health care reforms in recent years.
While the White...
The Trump administration's recent announcement of national security investigations into pharmaceutical imports has set up a potential collision course with one of the most significant health care reforms in recent years.
While the White...
Last week, I flagged the growing risk that tariffs could upend affordability in the generics market. This week, the Trump administration made it official: it’s launching national security investigations under Section 232 of the Trade...
Last week, I flagged the growing risk that tariffs could upend affordability in the generics market. This week, the Trump administration made it official: it’s launching national security investigations under Section 232 of the Trade...
As President Donald Trump’s administration introduces a series of tariffs aimed at rebalancing trade and boosting US manufacturing, one sector in particular is watching closely: pharmaceuticals. While drugs themselves may not be directly...
As President Donald Trump’s administration introduces a series of tariffs aimed at rebalancing trade and boosting US manufacturing, one sector in particular is watching closely: pharmaceuticals. While drugs themselves may not be directly...
The Supreme Court recently heard arguments in Federal Communication Commission (FCC) v Consumers’ Research, a case that I covered in February and one that could dramatically reshape federal agency authority through the nondelegation...
The Supreme Court recently heard arguments in Federal Communication Commission (FCC) v Consumers’ Research, a case that I covered in February and one that could dramatically reshape federal agency authority through the nondelegation...
On Tuesday, March 25, 2025, the Senate Finance Committee voted to advance Dr Mehmet Oz in his confirmation as the next head of the Centers for Medicare and Medicaid Services (CMS).1 The full Senate vote is expected “soon” (whatever that...
On Tuesday, March 25, 2025, the Senate Finance Committee voted to advance Dr Mehmet Oz in his confirmation as the next head of the Centers for Medicare and Medicaid Services (CMS).1 The full Senate vote is expected “soon” (whatever that...
Last week, I explored the $880 billion question facing Congress—whether lawmakers could achieve their budget goals without cutting Medicaid. This week, that question took center stage as Dr Mehmet Oz, President Trump's nominee to lead the...
Last week, I explored the $880 billion question facing Congress—whether lawmakers could achieve their budget goals without cutting Medicaid. This week, that question took center stage as Dr Mehmet Oz, President Trump's nominee to lead the...
I’d like to step away from administrative law for a moment to provide a quick update on Medicaid. With news coming from all sides, what does the future of Medicaid actually look like?
The House of Representatives narrowly passed a budget...
I’d like to step away from administrative law for a moment to provide a quick update on Medicaid. With news coming from all sides, what does the future of Medicaid actually look like?
The House of Representatives narrowly passed a budget...
The erosion of administrative law continues, and with it, the dismantling of decades-long precedent. In June, the Supreme Court overturned a 40-year-old doctrine that allowed federal agencies to interpret their own ambiguous statutes. Later...
The erosion of administrative law continues, and with it, the dismantling of decades-long precedent. In June, the Supreme Court overturned a 40-year-old doctrine that allowed federal agencies to interpret their own ambiguous statutes. Later...
The dust has barely settled from Robert F Kennedy Jr’s confirmation as Secretary of Health and Human Services (HHS), but the changes are already coming fast and furious—a key theme of the Trump Administration’s actions within the last several...
The dust has barely settled from Robert F Kennedy Jr’s confirmation as Secretary of Health and Human Services (HHS), but the changes are already coming fast and furious—a key theme of the Trump Administration’s actions within the last several...
Last week, I explored the potential revival of the nondelegation doctrine through Federal Communication Commission v Consumers’ Research. Today, I want to examine what this could mean for health care regulation by considering the parallels...
Last week, I explored the potential revival of the nondelegation doctrine through Federal Communication Commission v Consumers’ Research. Today, I want to examine what this could mean for health care regulation by considering the parallels...
"Timely transition to a specialty long-term acute care hospital (LTACH) allows critically ill patients to receive continued acute care and early rehabilitation in one location, both improving patient outcomes and shortening episodes of care,"...
"Timely transition to a specialty long-term acute care hospital (LTACH) allows critically ill patients to receive continued acute care and early rehabilitation in one location, both improving patient outcomes and shortening episodes of care,"...
A 48-week trial of tildrakizumab in patients with ankylosing spondylitis was terminated early after researchers found that the drug had no efficacy in comparison to placebo.
A 48-week trial of tildrakizumab in patients with ankylosing spondylitis was terminated early after researchers found that the drug had no efficacy in comparison to placebo.
“In some patients with COPD, type 2 inflammation may increase exacerbation risk and may be indicated by elevated blood eosinophil counts,” said researchers.
“In some patients with COPD, type 2 inflammation may increase exacerbation risk and may be indicated by elevated blood eosinophil counts,” said researchers.
Acalabrutinib monotherapy may be a cost-effective treatment option for Medicare patients with treatment-naïve chronic lymphocytic leukemia, according to recent findings.
Acalabrutinib monotherapy may be a cost-effective treatment option for Medicare patients with treatment-naïve chronic lymphocytic leukemia, according to recent findings.
Vaccine season includes influenza, COVID-19, and the newly approved vaccines for RSV, prompting questions about who should receive which vaccine and when, as well as concerns about the cost of obtaining them.
Vaccine season includes influenza, COVID-19, and the newly approved vaccines for RSV, prompting questions about who should receive which vaccine and when, as well as concerns about the cost of obtaining them.